Benzoic acid 4-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-[1,3]dioxolan-2-ylmethyl ester | 912643-62-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: Benzoic acid 4-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-[1,3]dioxolan-2-ylmethyl ester
• 英文别名: [4-(2,4-Dioxopyrimidin-1-yl)-1,3-dioxolan-2-yl]methyl benzoate；[4-(2,4-dioxopyrimidin-1-yl)-1,3-dioxolan-2-yl]methyl benzoate
• CAS: 912643-62-0
• 化学式: C₁₅H₁₄N₂O₆
• 分子量: 318.286
• InChiKey: PZDBZBTZPWBLGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  94.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Benzoic acid 4-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-[1,3]dioxolan-2-ylmethyl ester 在 劳森试剂 、 羟胺 作用下， 以 乙醇 、 水 、 1,2-二氯乙烷 为溶剂， 反应 32.0h， 生成
  参考文献：
  名称：

  N ⁴-Hydroxycytosine Dioxolane Nucleosides and Their Activity Against Hepatitis B Virus

  摘要：

  Novel racemic, D- and L-beta-dioxolane N-4-hydroxycytosine nucleosides have been synthesized and evaluated for their activity against hepatitis B virus. None of the synthesized nucleosides demonstrated selective anti-HBV activity.

  DOI：

  10.1081/ncn-200067414
• 作为产物：
  描述：

  尿嘧啶 、 (+/-)-4-acetoxy-2-(benzoyloxymethyl)-1,3-dioxolane 在 六甲基二硅氮烷 、 三氟甲磺酸三甲基硅酯 作用下， 以 二氯甲烷 为溶剂， 生成 Benzoic acid 4-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-[1,3]dioxolan-2-ylmethyl ester
  参考文献：
  名称：

  N ⁴-Hydroxycytosine Dioxolane Nucleosides and Their Activity Against Hepatitis B Virus

  摘要：

  Novel racemic, D- and L-beta-dioxolane N-4-hydroxycytosine nucleosides have been synthesized and evaluated for their activity against hepatitis B virus. None of the synthesized nucleosides demonstrated selective anti-HBV activity.

  DOI：

  10.1081/ncn-200067414

文献信息

• Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
  申请人：Schinazi Raymond F.

  公开号：US20100168052A1

  公开（公告）日：2010-07-01

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  本发明提供了一种用于治疗、预防和/或预防宿主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药物接受者中给予有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药，可选地在药学上可接受的稀释剂或赋形剂中。
• <i>N</i> ⁴-Hydroxycytosine Dioxolane Nucleosides and Their Activity Against Hepatitis B Virus
  作者：Jinfa Du、Laurent Hollecker、Junxing Shi、Byoung-Kwon Chun、Kyoichi A. Watanabe、Raymond F. Schinazi、Tammy Y. Nachman、Stefania Lostia、Lieven J. Stuyver、Michael J. Otto

  DOI：10.1081/ncn-200067414

  日期：2005.7.1

  Novel racemic, D- and L-beta-dioxolane N-4-hydroxycytosine nucleosides have been synthesized and evaluated for their activity against hepatitis B virus. None of the synthesized nucleosides demonstrated selective anti-HBV activity.